NASDAQ false 0001369568 0001369568 2025-02-26 2025-02-26

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): February 26, 2025

 

 

CATALYST PHARMACEUTICALS, INC.

(Exact Name Of Registrant As Specified In Its Charter)

 

 

 

Delaware   001-33057   76-0837053

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

355 Alhambra Circle  
Suite 801  
Coral Gables, Florida   33134
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (305) 420-3200

Not Applicable

Former Name or Former address, if changed since last report

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

  

Name of Exchange

on Which Registered

  

Ticker

Symbol

Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01

Other Events

On February 26, 2025, the Company issued a press release announcing its results of operations for the fourth quarter and fiscal year ended December 31, 2024 and providing a business update. A copy of the press release is attached hereto as Exhibit 99.1.

 

Item 9.01

Financial Statements and Exhibits.

 

(d)    Exhibits
99.1    Press release issued by the Company on February 26, 2025.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Catalyst Pharmaceuticals, Inc.
By:  

/s/ Michael W. Kalb

    Michael W. Kalb
    Executive Vice President and Chief Financial
Officer

Dated: February 26, 2025

 

3

Exhibit 99.1

Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth

Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Strong Commercial Performance

Q4 2024 Net Product Revenue of $141.8 Million, Fueled by Sustained Organic Growth of FIRDAPSE® and Continued Market Adoption of AGAMREE®

Pursuing Strategic Investments to Expand Market Presence and Accelerate Growth

Full Year 2025 Total Revenues Expected to be Between $545 Million and $565 Million, Reflecting Confidence in Continued Growth Momentum

Conference Call and Webcast to be Held on February 27, 2025, at 8:30 AM ET

CORAL GABLES, Fla., - February 26, 2025 - Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today reported financial results for the fourth quarter and full year 2024 and provided a business update.

“Our record 2024 performance is a reflection of Catalyst’s successful launch of AGAMREE and our continued outstanding commercial capabilities that fuel the momentum of our existing products,” said Richard J. Daly, President and CEO of Catalyst. “Achieving total revenues for 2024 of $491.7 million demonstrates the strength of our scalable business model and the dedication of our teams to patient care. In 2025, we intend to not only seek to continue successfully growing our revenues from sales of our existing products, but also to continue our robust business development efforts, our efforts to protect FIRDAPSE’s intellectual property, and our efforts to increase the geographical availability of FIRDAPSE for LEMS patients.”

Financial Highlights

 

For the Years Ended December 31,    2024      2023      %
Change		  
(in thousands, except per share data)                     

Product Revenue, Net

    $ 489,327      $ 396,502        23.4 % 

FIRDAPSE Product Revenue, Net

    $ 306,035      $ 258,426        18.4 % 

FYCOMPA Product Revenue, Net

    $ 137,251      $ 138,076        (0.6 %) 

AGAMREE Product Revenue, Net

    $ 46,041        N/A        N/A  

GAAP Net Income

    $ 163,889      $ 71,410        129.5 % 

Non-GAAP Net Income**

    $ 276,288      $ 141,642        95.1 % 

GAAP Net Income Per Share – Basic

    $ 1.38      $ 0.67        106.0 % 

Non-GAAP Net Income Per Share – Basic**

    $ 2.33      $ 1.33        75.2 % 

GAAP Net Income Per Share – Diluted

    $ 1.31      $ 0.63        107.9 % 

Non-GAAP Net Income Per Share – Diluted**

    $ 2.21      $ 1.25        76.8 % 

Cash and Cash Equivalents (as of December 31)

   $ 517,553      $ 137,636        276.0 % 

**

Statements made in this press release include non-GAAP financial measures. Such information is provided as additional information and not as an alternative to Catalyst’s financial statements presented in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-GAAP financial measures are intended to enhance an overall understanding of Catalyst’s current financial performance. Catalyst believes that the non-GAAP financial measures presented in this press release provide investors and prospective investors with an alternative method for assessing Catalyst’s operating results in a manner that Catalyst believes is focused on the performance of ongoing operations and provides a more consistent basis for comparison between periods. Non-GAAP financial measures should not be considered in isolation or as a substitute for comparable GAAP accounting. Further, non-GAAP measures of net income used by Catalyst may be different from and not directly comparable to similarly titled measures used by other companies.

Beginning with the third quarter of 2024, Catalyst no longer includes acquisition in-process research and development (“IPR&D”) in its non-GAAP financial measures. Reported non-GAAP net income for the year ended December 31, 2023, included $81.5 million in acquisition IPR&D relating to Catalyst’s acquisition, during the third quarter of 2023, of the North American license for AGAMREE, which had not yet been approved by the U.S. Food and Drug Administration (“FDA”) at the time of the acquisition. The commercialization was subsequently approved by the FDA during the fourth quarter of 2023. Prior period amounts have been revised to conform to the current period presentation. Catalyst has made this change to its presentation following discussions with the Staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission.

Full Year 2024 Financial Highlights:

Full year 2024 financial results underscore robust revenue expansion, supported by sustained organic momentum, a successful product launch, and strong portfolio performance.

 

  •  

Full year 2024 total revenues were $491.7 million, a 23.5% YoY increase.

 

  •  

FIRDAPSE® full year 2024 product revenue, net was $306.0 million, an 18.4% YoY increase.

 

  •  

AGAMREE® 2024 product revenue, net was $46.0 million, reflecting the strong commercial launch of the product.

 

  •  

FYCOMPA® full year product revenue, net was $137.3 million, despite differences in variable consideration (gross-to-net) in 2024 compared to the 2023 period, during which product revenue, net for FYCOMPA was booked under EISAI’s more favorable cost arrangements with distributors and government authorities.

 

  •  

License and other revenue for 2024 of $2.4 million, consisted primarily of a $2.1 million milestone payment earned upon DyDo Pharma, Catalyst’s sub-licensee for FIRDAPSE in Japan, receiving product approval to commercialize the product for the treatment of Lambert-Eaton myasthenic syndrome (“LEMS”) patients in Japan.

Fourth Quarter 2024 Financial Highlights:

Fourth-quarter 2024 financial performance was driven by ongoing organic product growth and the accelerating market uptake of AGAMREE.

 

  •  

Fourth quarter 2024 total revenues were $141.8 million, a 28.3% YoY increase.

 

  •  

FIRDAPSE Q4 2024 product revenue, net was $82.5 million, an 18.3% YoY increase.

 

  •  

AGAMREE Q4 2024 product revenue, net was $21.1 million.

 

  •  

FYCOMPA Q4 2024 product revenue, net was $38.2 million.

2024 Commercial and Regulatory Highlights:

 

  •  

Successfully launched AGAMREE (vamorolone) oral suspension in the U.S. on March 13, 2024, for the treatment of Duchenne muscular dystrophy in patients ages two years and older.

 

  •  

Received FDA approval on May 30, 2024, of an increased maximum daily dose of FIRDAPSE to 100 mg, enhancing treatment flexibility for healthcare providers treating LEMS patients.

 

  •  

Initiated the SUMMIT study in August 2024, an open-label, five-year follow-up study which seeks to further demonstrate the clinical value of AGAMREE and evaluate its use as a monotherapy and in combination with other treatment options. Also, Catalyst initiated work to support the evaluation of AGAMREE as a treatment for additional diseases.

Notable Strategic Partnerships and Agreements:

 

  •  

On January 8, 2025, announced that the Company had entered into a settlement agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc., (collectively Teva), which resolves the patent litigation brought by Catalyst and SERB in response to Teva’s Abbreviated New Drug Application seeking approval to market a generic version of FIRDAPSE prior to the expiration of the applicable patents. Pursuant to the terms of the agreement, Teva will not market its generic version of FIRDAPSE in the U.S. any earlier than February 25, 2035, absent the occurrence of other conditions. The two remaining ANDA litigations regarding FIRDAPSE continue.

 

  •  

DyDo Pharma, Catalyst’s sub-licensee for FIRDAPSE in Japan, received Japanese Ministry of Health, Labour and Welfare (MHLW) approval to commercialize FIRDAPSE in Japan on September 24, 2024. The product was launched in Japan on January 21, 2025. Catalyst anticipates generating future revenues through potentially receiving additional milestone payments and sales of FIRDAPSE at a transfer price on the product supplied to DyDo Pharma, in lieu of royalties.

 

  •  

On July 24, 2024, the Company entered into an exclusive sub-license agreement with KYE Pharmaceuticals (KYE) for the commercial rights to AGAMREE in Canada, in an effort to potentially increase patient access to AGAMREE.

2024 Industry Recognitions:

 

  •  

Recognized in the Deloitte Technology Fast 500™ as one of North America’s Fastest-Growing Companies.

 

  •  

Ranked 5th on Forbes’ 2025 list of America’s Most Successful Mid-Cap Companies.

 

  •  

Recognized among BioSpace’s 2025 Best Places to Work.

Fourth Quarter 2024 and Full Year 2024 Financial Results

Total revenues: Total revenues for the fourth quarter of 2024 were $141.8 million, compared to $110.6 million for the fourth quarter of 2023, representing an increase of approximately 28.3% YoY. Full year 2024 total revenues were $491.7 million, compared to $398.2 million for full year 2023, representing an increase of approximately 23.5% YoY.

Product revenue, net: Product revenue, net for the fourth quarter of 2024, was $141.8 million, compared to $109.1 million for the fourth quarter of 2023, representing an increase of approximately 30.0% YoY. Full year 2024 product revenue, net was $489.3 million, compared to $396.5 million for full year 2023, representing an increase of approximately 23.4% YoY.

Research and development expenses: In the fourth quarter of 2024, research and development expenses were $3.8 million, compared to $2.0 million in the fourth quarter of 2023. Research and development expenses for full year 2024 were $12.6 million, compared to $93.2 million for full year 2023, which included an $81.5 million IPR&D expense related to the acquisition of a North American license for AGAMREE in the third quarter of 2023.

Selling, general, and administrative expenses: Selling, general, and administrative expenses for the fourth quarter of 2024 were $44.2 million, compared to $42.0 million in the fourth quarter of 2023. Selling, general, and administrative expenses for full year 2024 were $177.7 million, compared to $133.7 million for full year 2023.

Amortization of intangible assets: Amortization of intangible assets was $9.3 million in the fourth quarter of 2024, compared to $9.1 million in the fourth quarter of 2023. Amortization of intangible assets was $37.4 million in full year 2024, compared to $32.6 million for full year 2023.

Operating income: Operating income for the fourth quarter of 2024 was $62.8 million, compared to $41.7 million in the fourth quarter of 2023, representing an increase of approximately 50.7%. Full year 2024 operating income was $195.1 million, compared to $86.8 million for full year 2023, representing an increase of approximately 124.8%.

GAAP net income: GAAP net income for the fourth quarter of 2024 was $55.9 million ($0.47 per basic and $0.44 per diluted share), compared to GAAP net income of $34.8 million ($0.33 per basic and $0.31 per diluted share) for the fourth quarter of 2023. GAAP net income for full year 2024 was $163.9 million ($1.38 per basic and $1.31 per diluted share), compared to full year 2023 GAAP net income of $71.4 million ($0.67 per basic and $0.63 per diluted share).

Non-GAAP net income: Non-GAAP net income for the fourth quarter of 2024 was $88.8 million ($ 0.74 per basic and $0.70 per diluted share), compared to non-GAAP net income of $60.1 million ($0.56 per basic and $0.53 per diluted share) for the fourth quarter of 2023. Non-GAAP net income for full year 2024 was $276.3 million ($2.33 per basic and $2.21 per diluted share), compared to full year 2023 non-GAAP net income of $141.6 million ($1.33 per basic and $1.25 per diluted share). Non-GAAP net income in all periods excludes from net income stock-based compensation, depreciation, amortization of intangible assets, and the income tax provision.

Cash and cash equivalents: Cash and cash equivalents were $517.6 million as of December 31, 2024.

More detailed financial information and analysis of our financial condition and results of operations can be found in our Annual Report on Form 10-K for fiscal year 2024, which was filed with the U.S. Securities and Exchange Commission on February 26, 2025.

2025 Outlook

For full year 2025, the Company expects total revenues to be between $545 million and $565 million, reflecting continued growth in product revenue, net from FIRDAPSE and AGAMREE.

The Company expects FIRDAPSE’s product revenue, net for fiscal 2025 to range between $355 million and $360 million. The Company anticipates an increase in Q1 2025 product revenue, net compared to Q1 2024 due to the temporary market dynamics following the Change Healthcare disruption in February 2024, which led to short-term shifts in prescription fulfillment patterns. These effects are expected to normalize in Q2 2025, with revenue trends aligning with longer-term projections for the remainder of the year.

AGAMREE’s product revenue, net for 2025 is expected to be between $100 million and $110 million, reflecting its continued market adoption and commercial momentum. As a reminder, the Company commercially launched AGAMREE on March 13, 2024.

FYCOMPA’s product revenue, net is forecasted to be between $90 million and $95 million, driven by ongoing market demand ahead of the anticipated loss of patent exclusivity at the end of May 2025, for FYCOMPA tablets, and December 2025, for FYCOMPA oral suspension, with expected entry of generic competition following each loss of exclusivity.

Cost of sales: AGAMREE royalties paid to the product licensor increase when AGAMREE product revenue, net exceeds $100 million in any calendar year. Further, the Company will be required to make a $12.5 million milestone payment to the product licensor once AGAMREE product revenue for the calendar year reaches $100 million. Further, the Company is required to pay royalties, based on net product revenue, to the product licensor for FYCOMPA following the loss of exclusivity.

Research and development expenses: Due to anticipated activities relating to the SUMMIT study and efforts seeking to begin the development of additional indications for AGAMREE, the Company anticipates research and development expenses in 2025, absent another acquisition, to be between $15.0 and $20.0 million. Further, if the Company completes an acquisition, its R&D expenses may become more significant.

Selling, general, and administrative expenses: The Company anticipates an increase in selling, general and administrative expenses in 2025 compared to 2024, primarily driven by increased headcount, including full year costs for individuals hired throughout 2024 in certain functional areas to support the growth of its business and its overall strategy as the Company focuses on expanding its product portfolio, including the separate commercial and medical field forces for FIRDAPSE and AGAMREE which is scheduled to commence at the beginning of the 2025 second quarter.

Tax rate: The Company anticipates that its effective tax rate will be relatively consistent for 2025 compared to 2024 and 2023.

Conference Call & Webcast Details

 

Date:

Time:

US/Canada Dial-in Number:

International Dial-in Number:

   

February 27, 2025

8:30 AM ET

(877) 407-8912

(201) 689-8059

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America’s Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.

For more information, please visit Catalyst’s website at www.catalystpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst’s actual results in future periods to differ materially from forecasted results. A number of factors, including (i) whether Catalyst’s revenue forecasts for 2025 that are included in this press release will prove to be accurate, (ii) whether Catalyst will continue to be profitable and cash flow positive in 2025 and beyond, (iii) whether Catalyst will complete any acquisitions of additional products, and the timing of any such acquisitions, (iv) the impact of the pending Paragraph IV litigation relating to FIRDAPSE if the results of these litigation matters are adverse, and (v) those factors described in Catalyst’s Annual Report on Form 10-K for the 2024 fiscal year and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst’s filings with the SEC are available from the SEC, may be found on Catalyst’s website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

CATALYST PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

 

     (Unaudited)
For the Three Months
Ended December 31,		      For the Years
Ended December 31,		  
     2024      2023      2024      2023  

Product revenue, net

    $ 141,809      $ 109,104      $ 489,327      $ 396,502

License and other revenue

      11      1,464        2,407      1,702
  

 

 

     

 

 

     

 

 

     

 

 

  

Total revenues

      141,820      110,568        491,734      398,204
  

 

 

     

 

 

     

 

 

     

 

 

  

Operating costs and expenses:

            

Cost of sales (a)

      21,643      15,809      68,845      51,967

Research and development

      3,798      1,972      12,648      93,150

Selling, general and administrative (a)

      44,192      42,036      177,740      133,710

Amortization of intangible assets

      9,344      9,059      37,377      32,565
  

 

 

     

 

 

     

 

 

     

 

 

  

Total operating costs and expenses

      78,977      68,876      296,610      311,392
  

 

 

     

 

 

     

 

 

     

 

 

  

Operating income

      62,843        41,692      195,124      86,812

Other income, net

      11,338        5,015      21,139      7,699
  

 

 

     

 

 

     

 

 

     

 

 

  

Net income before income taxes

      74,181        46,707      216,263      94,511

Income tax provision

      18,245        11,863      52,374      23,101
  

 

 

     

 

 

     

 

 

     

 

 

  

Net income

    $ 55,936      $ 34,844    $ 163,889      $ 71,410
  

 

 

     

 

 

     

 

 

     

 

 

  

Net income per share:

            

Basic

    $ 0.47      $ 0.33    $ 1.38    $ 0.67
  

 

 

     

 

 

     

 

 

     

 

 

  

Diluted

    $ 0.44      $ 0.31    $ 1.31    $ 0.63
  

 

 

     

 

 

     

 

 

     

 

 

  

Weighted average shares outstanding:

            

Basic

      119,892,062        106,714,944        118,457,673        106,279,736  
  

 

 

     

 

 

     

 

 

     

 

 

  

Diluted

      126,280,116        113,755,677        124,943,603        113,753,154  
  

 

 

     

 

 

     

 

 

     

 

 

  

 

(a)

exclusive of amortization of intangible assets

CATALYST PHARMACEUTICALS, INC.

RECONCILIATION OF NON-GAAP METRICS (unaudited)

(in thousands, except share and per share data)

 

     For the Three Months
Ended December 31,		      For the Years
Ended December 31,		  
     2024      2023      2024      2023  

GAAP net income:

    $ 55,936      $ 34,844    $ 163,889      $ 71,410  

Non-GAAP adjustments:

            

Stock-based compensation expense

      5,171      4,250        22,251        14,250  

Depreciation

      114      84        397        316  

Amortization of intangible assets

      9,344      9,059        37,377        32,565  

Income tax provision

      18,245        11,863        52,374        23,101  
  

 

 

     

 

 

     

 

 

     

 

 

  

Non-GAAP net income

    $ 88,810    $ 60,100      $ 276,288    $ 141,642
  

 

 

     

 

 

     

 

 

     

 

 

  

Non-GAAP net income per share:

            

Basic

    $ 0.74    $ 0.56      $ 2.33      $ 1.33
  

 

 

     

 

 

     

 

 

     

 

 

  

Diluted

    $ 0.70    $ 0.53      $ 2.21    $ 1.25  
  

 

 

     

 

 

     

 

 

     

 

 

  

Weighted average shares outstanding:

            

Basic

      119,892,062        106,714,944        118,457,673        106,279,736  
  

 

 

     

 

 

     

 

 

     

 

 

  

Diluted

      126,280,116        113,755,677        124,943,603        113,753,154  
  

 

 

     

 

 

     

 

 

     

 

 

  

CATALYST PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

 

     December 31,
2024		      December 31,
2023		  

Assets

      

Current Assets:

      

Cash and cash equivalents

    $ 517,553      $ 137,636  

Accounts receivable, net

      65,476        53,514  

Inventory

      19,541        15,644  

Prepaid expenses and other current assets

      21,039        12,535  
  

 

 

     

 

 

  

Total current assets

      623,609        219,329  

Operating lease right-of-use asset, net

      2,230        2,508  

Property and equipment, net

      1,354        1,195  

License and acquired intangibles, net

      156,672        194,049  

Deferred tax assets, net

      45,982        36,544  

Investment in equity securities

      21,564        16,489  
  

 

 

     

 

 

  

Total assets

    $ 851,411      $ 470,114  
  

 

 

     

 

 

  

Liabilities and Stockholders’ Equity

      

Current Liabilities:

      

Accounts payable

    $ 16,593      $ 14,795  

Accrued expenses and other liabilities

      104,085        61,268  
  

 

 

     

 

 

  

Total current liabilities

      120,678        76,063  

Operating lease liability, net of current portion

      2,786        3,188  

Other non-current liabilities

      315        2,982  
  

 

 

     

 

 

  

Total liabilities

      123,779        82,233  

Total stockholders’ equity

      727,632        387,881  
  

 

 

     

 

 

  

Total liabilities and stockholders’ equity

    $ 851,411      $ 470,114  
  

 

 

     

 

 

  

Source: Catalyst Pharmaceuticals, Inc.

Contact information:

Investor Contact

Mary Coleman, Catalyst Pharmaceuticals, Inc.

(305) 420-3200

IR@catalystpharma.com

Media Contact

David Schull, Russo Partners

(858) 717-2310

david.schull@russopartnersllc.com

v3.25.0.1
Document and Entity Information
Feb. 26, 2025
Cover [Abstract]  
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001369568
Document Type 8-K
Document Period End Date Feb. 26, 2025
Entity Registrant Name CATALYST PHARMACEUTICALS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-33057
Entity Tax Identification Number 76-0837053
Entity Address, Address Line One 355 Alhambra Circle
Entity Address, Address Line Two Suite 801
Entity Address, City or Town Coral Gables
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33134
City Area Code (305)
Local Phone Number 420-3200
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol CPRX
Entity Emerging Growth Company false
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Feb 2025 to Mar 2025 Click Here for more Catalyst Pharmaceuticals Charts.
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Mar 2024 to Mar 2025 Click Here for more Catalyst Pharmaceuticals Charts.